Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCGR siRNA LNP
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
GCGR siRNA LNP is a preclinical therapeutic platform consisting of a small interfering RNA (siRNA) targeting the glucagon receptor (GCGR) encapsulated within lipid nanoparticles (LNPs). This agent is designed to selectively downregulate GCGR expression in the liver, thereby inhibiting glucagon-mediated glycogenolysis and gluconeogenesis. In preclinical models of type 2 diabetes and obesity, hepatic knockdown of GCGR using this platform has been shown to significantly reduce blood glucose levels, improve oral glucose tolerance, and normalize glucose homeostasis. The platform has been utilized in research by organizations such as Merck Research Laboratories and academic institutions to investigate the therapeutic potential of targeting glucagon signaling.
- Other names
- Gcgr siRNA LNPglucagon receptor siRNA LNPhepatic GCGR siRNA LNP
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on GCGR siRNA LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCGR siRNA LNP.